Health Condition 1: L80- Vitiligo
Conditions
Interventions
None listed
Sponsors
Pigmentary Disorders Society India
Eligibility
Inclusion criteria
Inclusion criteria: Consecutive patients with clinical diagnosis of vitiligo vulgaris; and age > 18 years and The study shall include 40 consecutive patients having vitiligo (20 stable, 20 active) attending the Pigmentary Clinic of the Department of Dermatology, Venereology and Leprology at Postgraduate Institute of Medical Education and Research, Chandigarh. Controls: Ten healthy individuals (accompanying the patients and having no skin/ systemic disease) will be taken as controls.
Exclusion criteria
Exclusion criteria: Leucoderma secondary to other causes Pregnancy/Lactation Patients with severe hepatic, renal, thyroid or other systemic disorder Pre-existing malignancy Any other skin disease Patients receiving topical or systemic therapy of any form for vitiligo in past 6 weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the blood levels of soluble programmed death-1 (sPD-1) and soluble programmed death ligand-1 (sPD-L1) in patients having vitiligo through ELISA.Timepoint: To assess the blood levels of soluble programmed death-1 (sPD-1) and soluble programmed death ligand-1 (sPD-L1) in patients having vitiligo through ELISA at the time of recruitment. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To correlate the blood levels of sPD-1 and sPD-L1 with disease activity and severity (stable vs active; among different vitiligo disease activity [VIDA], and vitiligo area scoring index [VASI] scores). 2. To correlate the blood levels of sPD-1 and sPD-L1 with those of interleukins [IL]-2, 7 and 15; and interferon gamma (IFN-ï?§); which shall be measured through ELISA. Timepoint: cross-sectional | — |
Countries
India
Contacts
Public ContactAnuradha
Postgraduate Institute of Medical Education and Research
Outcome results
None listed